secwatch.observer — SEC 8-K summary
======================================

Issuer:     ANAPTYSBIO, INC (ANAB)
CIK:        0001370053
Form:       8-K
Filed at:   2025-11-04T23:59:59+00:00
Accession:  0001370053-25-000088
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AnaptysBio plans to separate biopharma ops from royalty assets by YE 2026; Q3 net income $15.1M
--------------------------------------------------------------------------------

- Intent to split into two public companies, one holding Jemperli royalties and milestones, the other advancing pipeline assets.
- Q3 2025 revenue $76.3M (up from $30.0M), net income $15.1M ($0.54/share) vs net loss of $32.9M in Q3 2024.
- Cash and investments $256.7M; expects ~$300M YE 2025 including $75M milestone from GSK when Jemperli hits $1B sales.
- Phase 2 top-line data for rosnilimab in ulcerative colitis expected Nov/Dec 2025; Phase 2b RA data positive.
- GSK's Jemperli Q3 sales $303M (+16% QoQ); annualized royalties for Anaptys >$390M at peak guidance.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1370053/000137005325000088/0001370053-25-000088-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1370053/000137005325000088/anab-20251104.htm
  HTML page:      https://secwatch.observer/filing/0001370053-25-000088

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer